Journal of Interventional Cardiology / 2022 / Article / Tab 3 / Research Article
Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions Table 3 Study endpoints associated with treatment methods.
Parameters EVT group (n = 94) Bypass group (n = 93) valueSuccessful intervention at one month 93 (100) 94 (100) Direct revascularization 43 (45.7) 47 (50.5) 0.512 Postintervention ABI One month 0.92 ± 0.1 0.95 ± 0.16 0.113 36 months 0.53 ± 0.16 0.72 ± 0.14 <0.001 Primary patency 12 months 70 (74.5) 76 (81.7) 0.231 24 months 52 (55.3) 62 (66.7) 0.112 36 months 37 (39.4) 55 (59.1) 0.007 Secondary patency 24 months 74 (78.7) 79 (84.9) 0.27 36 months 61 (64.9) 73 (78.5) 0.039 Male 25 (26.6) 31 (33.3) 0.315 AFSR at 36 months 64 (68.1) 71 (76.3) 0.208 LEA at 36 months 32 (34.0) 29 (31.2) 0.954 Major 8 (8.5) 8 (8.6) Minor 23 (24.5) 21 (22.6) 24-month mortality 15 (16.0) 9 (9.7) 0.199 36-month mortality 27 (28.7) 18 (19.4) 0.134 12-month CAD events 15 (16.0) 17 (18.3) 0.673 24-month CAD events 28 (29.8) 26 (28.0) 0.782 36-month CAD events 30 (31.9) 29 (31.2) 0.914 24-month CVA events 5 (5.3) 10 (10.8) 0.171 36-month CVA events 10 (10.6) 11 (11.8) 0.797 Concomitant medications Cilostazol treatment ≤3 months 31 (33.0) 23 (24.7) 0.213 >3 months 63 (67.0) 70 (75.3) Statin treatment 32 (34.0) 42 (45.2) 0.120 Antiplatelet therapy 93 (1001) 94 (100) 1.000
ABI, ankle brachial index; AFSR, amputation-free survival rate; CAD, coronary artery disease; CVA, cerebrovascular accident; EVT, endovascular therapy; LEA, lower-extremity amputation; MALE, major adverse limb event.